Page 42 - Evogene Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article REHOVOT, Israel, Jan. 21, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn's & Colitis Congress®  to be held from today January 21-24, 2021. Prof. Yehuda Ringel, CSO of Biomica, will present " BMC322 - A rationally-designed live bacterial consortium based on microbiome functional genomic analysis for treatment of IBD" on Saturday 23 rd Janua...

Share this article Share this article REHOVOT, Israel, Jan. 20, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference.  The conference is being held on January 28-29, 2021, virtually. Dr. Elran Haber, Biomica's Chief Executive Officer, is scheduled to speak on the European Microbiome Leaders Panel during the morning opening plenary sessi...

Shark Bites: A Computational Predictive Biology Play Upcoming catalyst are likely to put the stock on the radar screen of investors. Stocks quotes in this article: EVGN, ARKG Evogene Ltd.  (EVGN) is a small Israeli company that is using something called computational predictive biology to develop products in four different areas. Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biologic...

Organigram Plans To Ramp Up Staff Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) posted financial results for the first quarter of fiscal 2021. The company reported a net loss of $34.4 million, or 17 cents per share on a diluted basis, which compares to a net loss of $900,000, or one... Read More...

Lavie Bio Provides Product Pipeline Update for 2020 USA - English News provided by Share this article Share this article REHOVOT, Israel, Dec. 29, 2020 /PRNewswire/ -- Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial laun...